Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 15.53% | -12.07% | |||
| Gross Profit | -16.31% | 12.66% | |||
| SG&A Expenses | 4.90% | 17.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.56% | 3.14% | |||
| Operating Income | -5.87% | -2.83% | |||
| Income Before Tax | -44.36% | 55.61% | |||
| Income Tax Expenses | -90.77% | 1,081.82% | |||
| Earnings from Continuing Operations | -43.08% | 55.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.08% | 55.20% | |||
| EBIT | -5.87% | -2.83% | |||
| EBITDA | -5.87% | -3.07% | |||
| EPS Basic | -29.74% | 65.60% | |||
| Normalized Basic EPS | -30.89% | 65.91% | |||
| EPS Diluted | -29.35% | 65.53% | |||
| Normalized Diluted EPS | -30.89% | 65.91% | |||
| Average Basic Shares Outstanding | 10.28% | 30.22% | |||
| Average Diluted Shares Outstanding | 10.28% | 30.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||